Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436272 | 0.87 | MAOB (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27353753 | 0.82 | PTGS2 (0.54) | PTGS2MAOBCES2BCHECES1 | |
| SCHEMBL3569615 | 0.78 | PTGS2 (0.56) | PTGS2MAOBCES2BCHECES1 | |
| SCHEMBL3569619 | 0.78 | PTGS2 (0.56) | PTGS2MAOBCES2BCHECES1 | |
| SCHEMBL1339824 | 0.76 | PTGS2 (0.55) | PTGS2MAOBCES2BCHECES1 | |
| SCHEMBL1339826 | 0.76 | PTGS2 (0.55) | PTGS2MAOBCES2BCHECES1 | |
| SCHEMBL5425543 | 0.76 | SMN1; SMN2 (0.56) | BCHEMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5433951 | 0.75 | HDAC8 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL5427641 | 0.75 | SLC9A1 (0.42) | SLC9A1HTR2BMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5430628 | 0.74 | ALDH1A1 (0.48) | SLC9A1HTR2BMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | claimed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1646371-A2 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2006-04-19 | — | — | EP | claimed |
| WO-2004112687-A2 | ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2004-12-29 | — | — | WO | claimed |
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | disclosed |
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | disclosed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| EP-2617709-A1 | Guanidine derivatives as antiviral agents | Biotron Limited (AU) | 2013-07-24 | — | — | EP | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| CN-101111475-B | Antiviral compounds and methods | BIOTRON LTD | 2012-09-05 | — | — | CN | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 3834/4885SLC9A1 4403/4885GRIN2D 4590/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 3834/4885SLC9A1 4403/4885GRIN2D 4590/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 3863/4885SLC9A1 4386/4885GRIN2D 4621/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | PTGS2 3834/4885SLC9A1 4403/4885GRIN2D 4590/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | PTGS2 3893/4885SLC9A1 4316/4885GRIN2D 4607/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | PTGS2 3893/4885SLC9A1 4316/4885GRIN2D 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.